WSA
PGEN icon

Wall Street Associates’s Precigen PGEN Stock Holding History

Wall Street Associates’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-43,959
Closed -$1M – 330
2013
Q4 		$1M Sell
43,959
-2,950
-6% -$59.6K 0.08% 214
2013
Q3 		$1.06M Buy
+46,909
New +$1.08M 0.1% 207

Other funds holding PGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wall Street Associates's PGEN Position: Q1 2014 in Review

Wall Street Associates sold out of Precigen (PGEN) in Q1 2014, closing a stake of 43,959 shares — an estimated $1M sold.

Wall Street Associates first reported a position in PGEN in Q3 2013 and held it in 2 quarters. The position peaked at $1.06M in Q3 2013. 100 funds tracked by Wall St. Rank hold PGEN as of Q1 2014.

  • Wall Street Associates reported no remaining Precigen position as of Q1 2014 after selling out during the quarter.
  • Wall Street Associates sold 43,959 Precigen shares in Q1 2014, an estimated $1M.
  • Wall Street Associates first reported a position in Precigen in Q3 2013 and held it in 2 quarters.
  • Wall Street Associates's Precigen position peaked at $1.06M in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Precigen as of Q1 2014.

Based on Wall Street Associates's 13F filing for Q1 2014, filed 13 May 2014.